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Abstract
The IL-12 family of cytokines plays crucial functions in innate and adaptive immunity. These
cytokines include heterodimers sharing distinct 𝛼 (IL-12A, IL-23A, and IL-27A) with two 𝛽 (IL-12B
and Epstein-Barr virus induced gene 3 [EBI3]) chains, respectively, IL-12 (IL-12B plus IL-12A) and
IL-23 (IL-12B plus IL-23A) sharing IL-12B, IL-27 (EBI3 plus IL-27A), IL-35 (EBI3 plus IL-12A), and
IL-39 (EBI3 plus IL-23A) sharing EBI3. In this context, we have recently reported that highly pure
neutrophils incubated with TLR8 agonists produce functional IL-23. Previously, we showed that
neutrophils incubatedwith LPS plus IFN𝛾 for 20 h produce IL-12.Herein, we investigatedwhether
highly pure, TLR8-activated, neutrophils produce EBI3, and in turn IL-27, IL-35, and IL-39, the IL-
12 members containing it. We report that neutrophils incubated with TLR8 ligands, TNF𝛼 and,
to a lesser extent, LPS, produce and release remarkable amounts of EBI3, but not IL-27A, conse-
quently excluding the possibility for an IL-27 production. We also report a series of unsuccess-
ful experiments performed to investigate whether neutrophil-derived EBI3 associates with IL-
23A to form IL-39. Furthermore, we show that neutrophils incubated with IFN𝛾 in combination
with either TLR8 or TLR4 ligands express/produce neither IL-12, nor IL-35, due to the inability of
IFN𝛾 , contrary to previous findings, to activate IL12A transcription. Even IL-27 was undetectable
in supernatants harvested from IFN𝛾 plus R848-treated neutrophils, although theywere found to
accumulate IL27A transcripts. Finally, by immunohistochemistry experiments, EBI3-positive neu-
trophils were found in discrete pathologies only, including diverticulitis, cholecystitis, Gorham
disease, and Bartonella Henselae infection, implying a specific role of neutrophil-derived EBI3
in vivo.
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1 INTRODUCTION
During the last 30 yr, accumulating evidence has uncovered that
polymorphonuclear neutrophils, either in vitro under appropriate
Abbreviations: BM, bonemarrow; EBI3, Epstein-Barr virus induced gene 3; FPKM, fragments
per kilobase of transcript per millionmapped reads; IFIT, IFN-induced protein with
tetratricopeptide repeats 1; IL-1ra, IL 1 receptor antagonist; MNE, mean normalized
expression; pAbs, polyclonal antibodies; RNA-seq, RNA followed by high throughput
sequencing; RPL, ribosomal protein L; RT-qPCR, reverse transcription quantitative
polymerase chain reaction.
experimental conditions, or in in vivo diseases/experimental mod-
els, can produce a variety of cytokines in a highly regulated
fashion.1 Accordingly, the list of neutrophil-derived cytokines cur-
rently includes chemokines, ILs, members of the TNF family, growth
factors, and many others,1 hence implying that neutrophils may
be actively involved in physiopathologic processes that go beyond
their well-recognized pro/anti-inflammatory functions.2 Notably, the
majority of the cytokines that neutrophils can potentially generate
requires a stimulus-induced transcription of the related transcripts
and, in turn, their de novo synthesis and release.1,3 Experimental
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conditions shown to promote cytokine gene expression and produc-
tion by human neutrophils include ligands of pattern recognition
receptors, cytokines themselves, damage-associated molecular pat-
terns and phagocytosis.1 In addition, neutrophil-derived cytokines
can themselves enhance/generate additional cytokine expression via
autocrine feedback loops.3,4 In this context, we recently identi-
fied TLR8 ligands, such as R848, CL075, and VTX-2337, as stim-
uli inducing neutrophils to produce cytokines at higher levels than
other known agonists, as shown in the case of TNF𝛼, IL-6, G-CSF,
and CCL23 production.4-6 Nonetheless, when examining their poten-
tial capacity to express genes/produce a given protein/cytokine, one
should never forget that, on a per cell basis, activated neutrophils
accumulate at least 10- to 20-fold lower amounts of RNA, and/or
produce exceedingly lower cytokine concentrations than other leuko-
cyte types do.1 Therefore, to avoid false positive results in terms of
either patterns/amounts of cytokines produced, or cytokine mRNA
profiles expressed, it is mandatory to isolate neutrophils at the maxi-
mal purity (>99.7% ideally).7
Cytokines belonging to the IL-12 family play critical functions in
innate and adaptive immunity.8,9 They are composed of functional het-
erodimers that share distinct 𝛼- and 𝛽-subunits, namely, IL-12A/p35,
IL-23A/p19, and IL-27A/p28 as 𝛼-chains, and IL-12B/p40 and Epstein-
Barr virus-induced protein 3 (EBI3) as 𝛽-chains.8,10 A total of five IL-
12 family cytokines are currently known, precisely IL-12 (IL-12A plus
IL-12B), IL-23 (IL-23A plus IL-12B), IL-27 (IL-27A plus EBI3), IL-35 (IL-
12A plus EBI3),9 as well as the recently reported murine IL-39 (IL-23A
plus EBI3).11 Interestingly, individual subunits have also been shown
to have self-standing activities, as in the case of EBI3,12 intracellular
IL-23A,13 IL-12B homodimer (p80),14 and IL-27A (IL-30).15 IL-12 has
been the first identifiedmember of the family,16 which, similar to IL-23
and IL-27, is mainly produced by macrophages and dendritic cells.17,18
Differently, IL-35 is produced by activated B cells and forkhead box
P3+ Treg cells,19 whereas IL-39 seems to be produced by murine acti-
vated B cells.11 In this context, human neutrophils have been shown
to produce IL-12,20,21 IL-23,22 and IL-27A23 upon defined stimulatory
conditions. For instance, TLR8-activated neutrophils have been shown
to express and produce IL-12B, IL-23A, and IL-23, but not IL-12A,24
consequently excluding the possibility that they could release IL-12
and IL-35.
In this study, we extended our analysis on the ability of TLR8-
activated neutrophils to eventually express and produce EBI3, as
well as the IL-12 cytokine members containing it, including IL-
27 and IL-39. As a result, we report that neutrophils incubated
with either TLR8 or TLR4 ligands express and produce elevated
amounts of EBI3, but not IL-27A, consequently excluding the
possibility of an IL-27 production under the same stimulatory
conditions. We also report a series of unsuccessful experiments
performed to investigate whether neutrophil-derived EBI3 associates
with IL-23A to form IL-39. Finally, we show that neutrophils incu-
bated with IFN𝛾 in combination with either TLR8 or TLR4 ligands
express/produce neither IL-12 nor IL-35, due to the inability of IFN𝛾
to activate IL12A transcription, thus denying previous studies from
our group.20
2 MATERIALS AND METHODS
2.1 Cell purification and culture
Highly purified neutrophils (approximately 99.7% purity) were iso-
lated from the venous blood or buffy coats from healthy individu-
als, as already described.7 Human CD14+-monocytes (approximately
98% purity) were isolated by anti-CD14 microbeads (Miltenyi Biotec,
Bergisch Gladbach, Germany) from autologous PBMCs, previously
obtained from blood after Ficoll-Paque gradient centrifugation.4 Neu-
trophils and monocytes were then suspended at 5 × 106/ml and
2.5 × 106/ml, respectively, in RPMI 1640 medium containing 10% FBS
(with <0.5 EU/ml endotoxin, BioWhittaker-Lonza, Basel, Switzerland).
Cellswere incubated for up to 48h in the absence (control) or the pres-
ence of: 0.2–10 µM R848 (InvivoGen, San Diego, CA, USA); 1 µg/ml
ultrapureLPS (E. coli0111:B4 strain, InvivoGen); 10ng/mlhumanTNF𝛼
(R&DSystems,Minneapolis,MN, USA); 200U/ml IFN𝛾 (R&DSystems);
10ng/mlGM-CSF (Miltenyi Biotec); 1000U/mlG-CSF (Myelostim, Ital-
farmaco Spa, Milano, Italy); 0.2–10 µMCL075 (InvivoGen); 0.2–10 µM
VTX-2337 (Selleck Chem, Boston, MA, USA); or 10 µg/ml adalimumab
(Humira, Abbott Biotechnology Limited, Barceloneta, Puerto Rico).
2.1.1 Isolation ofmurine neutrophils
C57BL/6J mice, obtained from Jackson Laboratories (Bar Harbour,
ME, USA) were housed under specific pathogen-free conditions at the
University of Verona (Verona, Italy). Murine neutrophils were isolated
either frombonemarrow (BM), throughdiscontinuousPercoll gradient
centrifugation, according to standardprocedures,25 or fromperitoneal
exudates, harvested 16 h after i.p. injection of BioGel P Polyacrylamide
Beads (BioRad Laboratories, Hercules, CA, USA).4 Neutrophils were
then sorted by using a FACSAria II flow cytometer (Becton Dickinson,
Franklin Lakes,NJ,USA).4 Briefly, cell suspensionswere incubatedwith
APC Cy7-conjugated anti-mouse CD11b (M1/70), APC-conjugated
anti-mouse Ly6G (1A8), and Brilliant Violet 421-conjugated anti-
mouse CD45 (30-F11) antibodies (all from BioLegend), and then sus-
pended in PBS containing 2 mM EDTA, 1 mg/ml propidium iodide
(PI, for viability staining; Sigma-Aldrich, St. Louis, MO, USA) and 2%
FBS, before cell sorting. CD11b+Ly6G+ neutrophils (>99% pure) were
then suspended at 5 × 106/ml in RPMI 1640 medium, supplemented
with 10% FBS, 1% ultraglutamine, and 1% penicillin/streptomycin
(BioWhittaker-Lonza, Walkersville, MD, USA), and cultured (at 37◦C,
5% CO2), with or without 5 µM R848 or 1 µg/ml LPS or 10 ng/ml
TNF𝛼. All experiments were carried out in accordance with guidelines
prescribed by the Ethics Committee for the use of laboratory animals
for research purposes at the University of Verona, and by the Italian
Ministry of Health.
2.2 RNA isolation and reverse transcription
quantitative polymerase chain reaction (RT-qPCR)
After incubation, neutrophils and CD14+-monocytes were pelleted
by centrifugation and then total RNA was extracted by either
Trizol or RNeasy mini kit (Qiagen, Venlo, Limburg, Netherlands).26
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TABLE 1 List of primer sets utilized for the RT-qPCR experiments
Sequences














To remove any possible contaminant DNA, an on-column DNase
digestion with the RNase-free DNase set (Qiagen) was performed
during total RNA isolation.26 Total RNA was reverse-transcribed
into cDNA using Superscript III (Thermo Fisher Scientific, Waltham,
MA, USA) and random hexamer primers (Thermo Fisher Scientific,
Waltham, MA, USA).26 Transcript levels of individual genes were mea-
sured by RT-qPCR performed using Fast SYBR Green Master Mix
(Life Technologies, Carlsbad, CA, USA), using specific primer pairs
(Thermo Fisher Scientific) listed in Table 1. Data were calculated by
Q-Gene software (http://www.gene-quantification.de/download.html)
and expressed as mean normalized expression (MNE) units after
GAPDH normalization.26
2.3 RNA-seq
Total RNA from activated neutrophils was enriched for mRNA using
poly(A) selection. Standard Illumina (San Diego, CA, USA) proto-
cols were used to generate 50 bp single-end read libraries. In brief,
mRNA was fragmented, reverse transcribed, adapted with sequenc-
ing primers and sample barcodes, size selected, and finally PCR
enriched. Libraries were then sequenced on the Illumina NextSeq
500 platform.24 Reads were mapped to the reference human genome
(hg19) using TopHat version 2.0.14 and Bowtie 2 version 2. Gene
expression values (fragments per kilobase of transcript per million
mapped reads) were calculated using Cufflinks version 2.02. RNA-seq
signals were visualized using Integrative Genomics Viewer.27
2.3.1 Cytokine production
Cytokine concentrations in cell-free supernatants were measured by
commercially available ELISA kits, specific for human EBI3 (LSBio,
Seattle, WA, USA), IL-23A (Abcam, Cambridge, United Kingdom), IL-
12, IL-12B, IL-23, IL-23A, IL-27, and CXCL8 (Mabtech, Nacka Strand,
Sweden). The lowest detection limits of these ELISA were: 15 pg/ml
for EBI3, 6 pg/ml for IL-12, 10 pg/ml for IL-12B, 4 pg/ml for IL-23,
20 pg/ml for IL-23A, 32 pg/ml for IL-27, and 4 pg/ml for CXCL8. To
develop an ELISA for IL-39, we used either 1–10 µg/ml anti-human
EBI3 mAbs (MAB6456 from R&D Systems) or 1–10 µg/ml anti-human
EBI3 mAbs (LS-C314301 from LSBio) as coating antibodies, and 1–
10 µg/ml biotinylated anti-human IL-23p19mABs (cloneMT155, from
Mabtech) as detection ones. To immunoprecipitate IL-39 from super-
natants of human neutrophils and CD14+-monocytes incubated with
IFN𝛾 plusR848,weused anti-humanEBI3 polyclonal antibodies (pAbs)
andmAbs (H-110 andG-4, respectively, both from Santa Cruz, Biotech
(Santa Cruz, CA, USA) and anti-human IL-23p19 pAbs and mAbs (H-
113 and C-3, respectively, both from Santa Cruz, Biotech (Santa Cruz,
CA, USA)). Recombinant human (rh) proteins used in these latter
experiments were: rhEBI3 (ab123759 from Abcam), rhIL-23p19 (Ori-
gene, Rockville, MD, USA), rhIL-35 (Peprotech, Rocky Hill, NJ, USA),
rhIL-27 (Miltenyi Biotec), and rhIL-39-Fc Chimera Protein (R&D Sys-
tems).
2.3.2 ELISA for human IL-39
To try detecting IL-39, microtitration 96-well plates (Nunc, Roskilde,
Denmark) were coated overnight at 4◦C with 50 µl of 1 to 10 µg/ml
anti-human EBI3 mAbs (MAB6456 from R&D Systems), or alterna-
tively, 1 to 10 µg/ml anti-human EBI3 mAbs (LS-C314301 from LSBio),
then washed with PBS-0.05% Tween 20 (PBS-T), and blocked with
100 µl of PBS-5% BSA for 2 h. Samples (50 µl) were added to the wells
and incubated for 2 h at room temperature. Afterwashing, biotinylated
anti-human IL-23A mAbs (clone MT155, from Mabtech) was added at
1 to 10 µg/ml and incubated for 2 h at room temperature. After wash-
ing, 50 µl of PBS containing streptavidin HRP (Sigma, St. Louis, MO,
USA) diluted 1:2000 was added and the plates incubated for 30min at
room temperature. Wells were further washed with PBS-T, reactions
developed by adding 50 µl of tetramethylbenzidine solution (Sigma)
and stopped after 30 min by adding 50 µl of 1 M H2SO4. As done by
Wang et al.11 for murine IL-39, a mixture of 10 ng/ml rhEBI3 and rhIL-
23Awas used as IL-39 standard. Optical density was read at 450 nm.
4 CASSATELLA ET AL.
2.3.3 Immunoblotting experiments
Whole lysates from resting/activated neutrophils and CD14+-
monocytes were recovered from protein-rich flow-through solutions
after the first centrifugation step of the RNeasy mini kit procedure
used for total RNA extraction, as previously described.6 Protein-rich
flow-through from neutrophils were then immunoblotted by stan-
dard procedures4 using anti-human EBI3 mAbs (clone 2G4H6)28
and anti-human 𝛽-actin mAbs (A5060 from Sigma). Blotted proteins
were detected by the Odyssey infrared imaging system (LI-COR
Biosciences, Lincoln, NE, USA).6
2.3.4 Immunohistochemistry
Human tissues, collected for diagnosis purposes, were retrieved from
the tissue banks of the Department of Pathology of Cochin Hospi-
tal (Paris) and the Department of Pathology of Spedali Civili di Bres-
cia (Brescia, Italy). Before staining, formalin-fixed paraffin-embedded
tissues were subjected to antigen retrieval by heat pretreatment in
citrate buffer (pH 6) or EDTA buffer (pH 8.0). Immunostaining was
performed using either an indirect alkaline phosphatase kit (Bio-
Genex, Fremont, CA, USA) and permanent red as chromogen, or using
Novolink Polymer (Leica Microsystems, Wetzlar, Germany) followed
byDAB (3,3’-diaminobenzidine). EBI3wasdetectedbyusing themouse
monoclonal anti-EBI3Ab (clone 2G4H6)28 at 2–4 µg/ml. Sectionswere
counterstained withMayer hematoxylin.
2.4 Statistical analysis
Data are expressed as mean ± SEM. Statistical evaluation was per-
formed by using, depending on the experimental data, Student’s t-test,
1-way ANOVA followed by Tukey’s post hoc test or 2-way ANOVA fol-
lowedbyBonferroni’s post hoc test.P values<0.05were considered as
statistically significant.
2.5 Study approval
Human sampleswere obtained following informed,written, consent by
healthy donors, in accordance with the Declaration of Helsinki. This
study was carried out in accordance with the recommendations of
Ethic Committee of the AziendaOspedaliera Universitaria Integrata di
Verona (Italy).
3 RESULTS
3.1 Expression and production of EBI3 by human
neutrophils treatedwith TLR8 and other agonists
Preliminary RNA-seq studies of highly pure neutrophils incubated
in the absence and the presence of 5 µM R848, for 6 and 20 h,
revealed a remarkable induction of EBI3mRNAunder R848-activating
conditions (Fig. 1A). Given that EBI3 may form IL-27, IL-35, and
IL-39, we performed RT-qPCR kinetic experiments of EBI3, IL27A,
and IL12A mRNA expression in neutrophils and autologous CD14+-
monocytes incubated not only with or without R848, but also with
1 µg/ml LPS (Fig. 1B). We have in fact already shown that both R848-
and LPS-treated neutrophils produce IL-23,24 implying that they also
express IL23A mRNA, as formally demonstrated in the case of R848-
treatment.24 Results shown in Figure 1B not only supported the RNA-
seq data, but also indicated that the optimal incubation time to induce
maximal expression of EBI3 mRNA in both neutrophils and CD14+-
monocytes corresponds to 20 h. Similar to IL12A,24 IL27A mRNA was
undetectable in R848- and LPS-treated neutrophils, at all time points
investigated (Fig. 1B). By contrast, IL27A and IL12A mRNAs were
weakly induced by R848 in CD14+-monocytes, withmaximum expres-
sion at 12 h. EBI3mRNA in neutrophils and CD14+-monocytes, as well
as IL27A and IL12AmRNA in CD14+-monocytes, were induced also by
LPS, but at lower levels than R848 (Fig. 1B).
Consistent with the gene expression data, neutrophils and CD14+-
monocytes were found to produce and release higher amounts of EBI3
in response to R848 than to LPS, at statistically significant levels only
in the case of neutrophils (Fig. 1C). Under the same stimulatory con-
ditions, the pattern of CXCL8 production was found similar to that
of EBI3 (Fig. 1C), but it is evident that CD14+-monocytes release
CXCL8 at levels at least 60-fold higher than neutrophils, as one would
have expected.29 Further demonstrations that activated neutrophils
(and CD14+-monocytes) produce EBI3 were obtained by Western
blot experiments detecting the cytokine in their whole cell lysates
(Fig. 2A), as well as by immunohistochemistry staining of diseased tis-
sues, revealing EBI3-positive neutrophils in Gorham disease (Fig. 2B),
diverticulitis (Fig. 2C-E), cholecystitis (Fig. 2F), and two cases of Bar-
tonella Henselae infection with suppurative lymphadenitis (Fig. 2G, H).
By contrast, in primary carcinomas and related lymph node metas-
tases, folliculitis, dermatitis, psoriasis, lichen planus, molluscum con-
tagiosum, granulomatous lymphadenitis, appendicitis, Chron’s disease,
and COVID-19 pneumonia, neutrophils turned out as EBI3-negative.
In another series of experiments, only TNF𝛼 (10 ng/ml), but not
G-CSF (1000 U/ml) or GM-CSF (10 ng/ml), was found able to trig-
ger the expression of EBI3 mRNA in neutrophils incubated for 20 h,
at levels comparable to those induced by R848 (Fig. 3A). By contrast,
IL1RN mRNA accumulation was found increased in both GM-CSF-
and G-CSF-, other than in R848-, LPS-, and TNF𝛼-treated neutrophils
(Fig. 3A), in line with previous data,29 whereas IL27AmRNA remained
undetectable under all experimental conditions (data not shown).
Because R848-treated neutrophils are known to release elevated
amounts of TNF𝛼,4 we then examined whether endogenous TNF𝛼
could autocrinally regulate the expression of EBI3mRNA, and found it
to be the case. Indeed, incubation of neutrophils with R848 for 20 h, in
the presence of 10µg/ml adalimumab (a TNF𝛼 neutralizing antibody)30
revealed a 44.7 ± 11.7% inhibition of EBI3 mRNA expression as com-
pared to cells incubated in its absence (n = 4). Interestingly, we also
found that, whereas the amounts of extracellular EBI3 detected in
supernatants from neutrophils incubated with R848 and/or TNF𝛼 for
20 h were substantially similar (Fig. 3B), at the same time point
the EBI3 mRNA levels were additively increased (Fig. 3C). Finally,
neutrophils incubated with other TLR8 ligands, namely, CL075,31
or Motolimod/VTX-233,32 displayed, similar to R848, up-regulatory
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F IGURE 1 EBI3 mRNA and protein expression in neutrophils and CD14+-monocytes incubated with R848 or LPS. In (A), highly pure neu-
trophils (5 × 106/ml) were incubated for 6 or 20 h in the absence (−) or the presence of 5 µM R848. Expression levels of EBI3 transcripts were
measured by RNA-seq (one representative experiment out of four is shown). In (B) 5 × 106/ml highly pure neutrophils and 2.5 × 106/ml CD14+-
monocytes were incubated for up to 48 h in the presence or the absence of 5 µM R848 or 1 µg/ml LPS. Plots show kinetics of EBI3, IL27A, and
IL12AmRNA expression, asmeasured by RT-qPCR and depicted asmean normalized expression (MNE) units after normalization toGAPDHmRNA
(mean ± SEM, n = 4–8). Asterisks indicate significant differences between LPS and R848 in terms of EBI3, IL27A, and IL12A mRNA induction:
*P< 0.05, **P< 0.01, ***P< 0.001, by 2-way ANOVA followed by Bonferroni’s posttest. (C) Cell-free supernatants were collected from 5 × 106/ml
neutrophils and 2.5 × 106/ml CD14+-monocytes incubated with R848 or LPS for 20 h, and the levels of EBI3 and CXCL8 extracellular proteins
measured by ELISA (n = 4–6). Asterisks indicate significant differences between R848 and LPS in terms of induced EBI3 and CXCL8 production:
*P < 0.05, **P < 0.01, and ***P < 0.001, by 1-way ANOVA followed by Tukey’s posttest. For (B) and (C), data are normalized per equal number
of cells
effects on the mRNA levels of EBI3, IL12B, IL23A (Fig. 3D), but not of
IL27A and IL12A (data not shown), in a dose-dependent fashion. Collec-
tively, these data prove that highly pure human neutrophils incubated
withTLR8 ligands andTNF𝛼 genuinely express andproduceEBI3.Data
also show that TLR8-activated neutrophils accumulate neither IL12A,
nor IL27A mRNAs, implying that they cannot produce either IL-35 or
IL-27.
3.2 Expression of EBI3 transcripts inmurine
neutrophils
To evaluate whether EBI3 mRNA could be expressed also by murine
neutrophils, the latter cells were isolated from the BM and inflamed
peritoneum, and then subjected to an in vitro incubation with 5 µM
R848, 1 µg/ml LPS and 10 ng/ml TNF𝛼. After 6 and 20 h, neutrophils
were harvested and lysed for total RNA purification. As shown in
Figure 4, activated neutrophils were found to accumulate EBI3 tran-
scripts, but differently from their human counterpart, LPS resulted the
strongest stimulus, regardless their source. Under the same experi-
mental conditions, IL12B mRNA accumulation was detected only in
BM, but not peritoneal, neutrophils, at higher levels in response to
R848 than LPS (Fig. 4).
3.3 Effect of IFN𝜸 on the expression of EBI3 and
other IL-12 familymembers by neutrophils
coincubatedwith either R848 or LPS
We have previously published that neutrophils incubated for 20 h
with LPS in combination with IFN𝛾 produce IL-12, given the abil-
ity of LPS to induce the expression of IL12B (but not IL12A, mRNA)
and of IFN𝛾 to induce that of IL12A (but not IL12B) mRNA.20 We
therefore incubated highly pure neutrophils with IFN𝛾 in the pres-
ence of either R848 or LPS, with the expectation of detecting,
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F IGURE 2 Antigenic EBI3 expression in human neutrophils. (A),
Immunoblot displaying antigenic EBI3 and actin expression in lysates
of neutrophils and autologous CD14+-monocytes cultured for 20 h
with or without 5 µM R848 (representative experiment, n = 2). (B-
H), Sections from tissues of patients affected by Gorham Disease (B),
diverticulitis (C–E), cholecystitis (F) and Bartonella Henselae infections
showing suppurative lymphadenitis (G, H) were stained with anti-EBI3
mousemonoclonal antibodies and counterstained withMeyer’s hema-
toxylin. Panels B–F were stained by using an indirect alkaline phos-
phatase kit and permanent red as chromogen, whereas panelsG andH
were stained by using Novolink polymer followed by DAB, as detailed
in Materials and Methods. Original magnifications: 100× (B–F) and
60× (G, H)
concomitantly with EBI3 mRNA accumulation, also IL12A transcripts.
To our surprise, however, RT-qPCR experiments revealed that IL12A
transcripts do not actually accumulate in neutrophils incubated with
IFN𝛾 , if either used alone, or in combination with either R848 or
LPS (Fig. 5A), thus excluding the possibility for an IL-12 or an IL-
35 production. Interestingly, although R848, LPS or IFN𝛾 were found
unable to induce IL27A mRNA expression in neutrophils, IFN𝛾 plus
either R848 or LPS triggered detectable levels of IL27A transcripts
(Fig. 5A). In any case, the efficacy of IFN𝛾 was confirmed by its
direct, time-dependent, induction of IFN-induced protein with tetra-
tricopeptide repeats 1 (IFIT1) mRNA expression (Fig. 5A), as well
as by its statistically significant, up-regulatory, actions on the R848-
and LPS-mediated induction of IL23A and, as expected,20 IL12B
genes (Fig. 5A).
Measurement of cytokine levels in the corresponding cell-free
supernatants uncovered that IFN𝛾 increases the production of IL-
12B, IL-23A, and IL-23, but not EBI3, by neutrophils coincubated
with R848 (Fig. 5B), as well as that of IL-23 by neutrophils coincu-
bated with LPS (Fig. 5B). Even in CD14+-monocytes, IFN𝛾 was found
unable to up-regulate the production of EBI3 in response to both
R848 and LPS, whereas it modulated the production of IL-12B, IL-
23A, and IL-23 almost similar (but not identically) to its actions on
neutrophils (Fig. 5B). ELISA measurements also confirmed, at pro-
tein level, the lack of IL-12 production by activated neutrophils,
while evidencing a remarkable potentiation by IFN𝛾 of the scarce IL-
12 release by CD14+-monocytes treated with either R848 or LPS7
(Fig. 5B). Even under “priming” conditions for CD14+monocytes,33
namely, after a 6 h preincubation with IFN𝛾 followed by a 18 h stim-
ulation with R848, neutrophils did not produce and release IL-12
(data not shown). Finally, IL-27 was not detected in cell-free super-
natants harvested from neutrophils incubated under all culture condi-
tions, in contrast towhatobservedwith autologousCD14+-monocytes
treated with R848 and cultured in the presence or the absence of
IFN𝛾 (Fig. 5B).
Altogether, data show that IFN𝛾 does not modulate the expres-
sion/production of EBI3 either in TLR-activated neutrophils or in
autologous CD14+-monocytes. Data also exclude that neutrophils
could produce IL-35, even if incubated with IFN𝛾 plus either R848
or LPS. Finally, data also negate previous publications on the in
vitro production of IL-12 by human neutrophils incubated with
IFN𝛾 plus LPS,20 extending such inability to the treatment with IFN𝛾
plus R848.
3.4 Investigation on the eventual ability of human
neutrophils to produce IL-39
It has been recently described that EBI3 associateswith IL-23A to form
IL-39, at least in murine activated B cells.11 However, although IL-39
has been shown to mediate inflammation in lupus-like mice,11 no con-
vincing evidence for its effective synthesis in humans actually exists.34
Given the expression of antigenic EBI3 (this study) and IL-23A24
by activated neutrophils,24 we decided to check whether the latter
cells could manufacture and secrete IL-39, even though no specific
reagents recognizing or measuring human IL-39 are currently avail-
able. Initially, we tried to immunoprecipitate IL-39 putatively present
in supernatants from IFN𝛾 plus R848-treated neutrophils/monocytes,
using either rabbit polyclonal or mouse monoclonal anti-IL-23A anti-
bodies ([both from Santa Cruz, Biotech (Santa Cruz, CA, USA) and
already shown to detect recombinant IL-23 by immunoblotting35],
followed by either rabbit polyclonal or mouse monoclonal anti-EBI3
antibodies36 [Santa Cruz, Biotech (Santa Cruz, CA, USA)]), and vice
versa, but our attempts were not successful (data not shown), even
using a mixture of equal amounts (1 µg) of rhIL-23A and rhEBI3 as
control, as it was previously found to form a stable complex.11 Then,
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F IGURE 3 Effect of TLR8 ligands and other agonists on EBI3mRNA expression by neutrophils. (A) 5 × 106/ml neutrophils were cultured with
or without 5 µM R848, 10 ng/ml TNF𝛼, 1 µg/ml LPS, 1000 U/ml G-CSF and 10 ng/ml GM-CSF to evaluate EBI3 and IL1ra mRNA expression by
RT-qPCR (n = 32). Asterisks stand for significant differences as compared to untreated cells: *P < 0.05, ***P < 0.001, by 1-way ANOVA followed
by Tukey’s posttest. (B–C) Neutrophils were cultured with or without 5 µM R848 and/or 10 ng/ml TNF𝛼 for 20 h, to evaluate their EBI3 release
by ELISA (B) and EBI3 mRNA expression by RT-qPCR (C). Values represent the means ± SEM (n = 2–4). Asterisks indicate a significant increase
exerted by R848 plus TNF𝛼 as compared with either R848 or TNF𝛼 singly used: *P < 0.05, ***P < 0.001, by Student’s t-test. (D) Neutrophils were
culturedwith orwithoutR848 (0.2–10µM),CL075 (0.2–10µM), orVTX-2337 (0.2–10µM), to evaluate EBI3, IL12B, and IL23AmRNAaccumulation
by RT-qPCR. Results from a representative experiment out of two are depicted as mean normalized expression (MNE) units after normalization to
GAPDHmRNA
we tried to develop an ELISA to detect human IL-39, as described in
Materials and Methods. However, no increased absorbance over the
blanks were obtained from supernatants harvested from IFN𝛾 plus
R848-treated neutrophils, as well as from IFN𝛾 plus LPS-treated
monocyte-derived DCs, which, in our hands, accumulate the highest
levels of EBI3 and IL23AmRNA (data not shown).
In sum, our experiments on a presumed association of extracellular
EBI3with IL-23A releasedby activatedneutrophils have collectedneg-
ative results only. It is also important to remark, in this context, that
the amount of IL-23A released by neutrophils incubated with R848
alone, or with IFN𝛾 plus R848 (shown in Fig. 5B), stoichiometrically
corresponds, more or less, to the IL-23 measured in the correspond-
ing supernatants,24 thus suggesting that IL-23A is unavailable for an
eventual association with EBI3 to form IL-39.
4 DISCUSSION
In the last years, our studies on the capacity of human neutrophils to
produce cytokines haveonly in part focusedon themembers belonging
to the IL-12 family. In 1995, we published that neutrophils express and
release IL-12 in vitro, when co-treated with LPS in combination with
IFN𝛾 for at least 20 h, but not with the two agonists used alone.20 At
molecular level, such synergismwas investigated by RNAse protection
assay (RPA) experiments, which revealed that LPS induces the expres-
sion of IL12B, but not IL12A, mRNA, whereas IFN𝛾 induces IL12A, but
not IL12B, transcripts.20 Our paper was then followed by other in
vitro studies, in which the requirement of IFN𝛾 in combination with
another agonist to trigger heterodimeric IL-12 production was sub-
stantially confirmed.21 More recently, confirming previous notions,22
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F IGURE 4 EBI3 and IL12B mRNA expres-
sion in murine neutrophils incubated with
R848, LPS, andTNF𝜶.Neutrophilswere isolated
from peritoneal exudates and bone marrow of
C57BL/6mice, suspended at 5×106/ml, and cul-
tured with or without 5 µM R848, 1 µg/ml LPS,
and 10 ng/ml TNF𝛼 for 6 and 20 h, to evalu-
ate their EBI3 and IL12B mRNA expression by
RT-qPCR. Results from a representative exper-
iment out of two are depicted as mean normal-
ized expression (MNE) units after normalization
toGAPDHmRNA
we have discovered that highly pure neutrophils incubated with TLR8
ligands, including R848, produce measurable quantities of extracel-
lular IL-23, as a result of a time-dependent induction of IL-12B and
IL23A transcripts.24 Notably, we also found that supernatants from
neutrophils, but not CD14+-monocytes, treated with R848, promote
the differentiation of naïve cord blood T lymphocytes into Th17 cells in
an IL-23-dependent fashion,24 thus indicating that neutrophil-derived
IL-23 is biologically active in vitro.
In this study, we have investigatedwhether TLR8 ligands trigger the
expression of other IL-12 family members by neutrophils. First of all,
we report that highly pure neutrophils incubated in vitro with R848,
CL075, or Motolimod/VTX-233, express, produce, and release EBI3
(as detected either by ELISA or immunoblot), at levels almost com-
parable to those produced by autologous CD14+-monocytes treated
under the same experimental conditions. If one takes into account that
the amounts of cytokines released from human neutrophils in vitro
are, in most cases, orders of magnitude lower than those produced by
monocytes,1,29 the quantity of EBI3 produced by activated neutrophils
herein found should be considered as really remarkable. This implies
that activated neutrophils represent major sources of EBI3, and, as
such, theymust have a potentially undoubted relevance in vivo.
Because EBI3 typically (but not necessarily) associates with other
subunits of the IL-12 family members, namely, IL-12A to form IL-
35, IL-27A to form IL-27 and, presumably, IL-23A to form IL-39, we
then sought whether activated neutrophils could generate those het-
erodimeric cytokines. Subsequent experiments uncovered that R848-
, as well as LPS-, treated neutrophils neither express IL27A mRNA
nor, confirming previous data,24 accumulate IL12A transcripts, thereby
excluding the formationof either IL-27or IL-35.Under the sameexper-
imental conditions, CD14+-monocytes were instead found to express
both IL27A and IL12A transcripts, as well as to release IL-12 and IL-
27, as expected.18,37 The lack of IL27AmRNA expression in R848- and
LPS-treated neutrophils, further confirmed by the failure to detect
IL-27 in the related supernatants, are in contrast with the results by
Rinchai et al.,23 who reported that neutrophils incubated for 6 and
24 h with B. pseudomallei, E.coli, and even LPS from E. coli, but not
with S. aureus, release amounts of IL-27A in the range of 2000/3000
pg/ml. Rinchai et al.23 also found that, in B. pseudomallei-treated neu-
trophils, the use of a high affinity WSX-1 soluble receptor (sIL-27RA)
to block the biologic activity of IL-27, partially suppressed neutrophil
oxidativeburst and cytokineproduction, in turn reducing their antibac-
terial activity, and indicating a neutrophil-activating effect by endoge-
nous IL-27.23 AlthoughB. pseudomalleiwasnot usedas a stimulus in our
study, and even if we utilized the same commercial ELISA, we have no
concrete hints explaining why our findings, at least in the case of LPS
stimulation, are so much in conflict with those by Rinchai et al.23 One
determining factor could be the purity of the neutrophil populations,
which, in the study by Rinchai et al.23 is declared as “generally as more
than 95%,” and thus in our opinion not sufficient enough to guarantee
the data veracity.7
Wealsomadea fewattempts todeterminewhetherTLR8-activated
neutrophils could produce and/or release IL-39 in vitro, in light of
their known capacity to express IL23A mRNA and to produce IL-
23.24 Accordingly, we tried to co-immunoprecipitate EBI3with IL-23A,
and vice versa, from supernatants harvested from R848-treated neu-
trophils, as well as to develop a specific ELISAmeasuring human IL-39.
Althoughwe only collected a series of negative results on all fronts, we
cannot actually draw any definitive conclusion, due to the unavailabil-
ity of specific reagents/positive controls to certify the quality of our
experiments. On the other hand, simply based on the amounts of EBI3,
IL-23A, and IL-23 measured in supernatants harvested from R848-
treated neutrophils, we calculated that—even with the limit of having
used ELISAs from three different companies—roughly, the amount of
IL-23A produced by activated neutrophils is fully employed to form
IL-23. In any case, the issue of IL-39 production by any kind of cell
will be likely solved only when reliable reagents specific for the human
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F IGURE 5 Effect of IFN𝜸 on the mRNA expression and production of EBI3 and other IL-12 family members by R848- or LPS-treated neu-
trophils and CD14+-monocytes.A total of 5 × 106/ml neutrophils and 2.5 × 106/ml CD14+-monocytes were cultured with or without 5 µMR848
and 1 µg/ml LPS, in combination or not with 200U/ml IFN𝛾 , for 6 and 20 h, to evaluate: (A) EBI3, IL12B, IL23A, IL27A, and IFIT1mRNA expression in
(continued on the next page)
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cytokine will be developed, of course assuming that IL-39 really exists
in humans. In fact, a recent report focused on the detection of the
potential pairings of IL-12 family chains in a system of HEK293T cells
co-expressing a set of each possible 𝛼-/𝛽-subunit combination,38 actu-
ally failed to detect the EBI3/IL-23A combination (alias IL-39), but not
other IL-12 family pairings.
In additional experiments, we cultured neutrophils with R848 and
IFN𝛾 , with the expectation to find an expression/production of IL-35,
based on the presumed capacity of IFN𝛾 to trigger the expression of
IL12A (and EBI3) mRNA by neutrophils.20 However, contrary to our
expectations, we found that IFN𝛾 does not actually trigger any expres-
sion of IL12A mRNA in highly pure neutrophils, as measured by RT-
qPCR (which is certainly more sensitive than the RPA used in 1995).20
On the other hand, under the same experimental conditions, IFN𝛾 was
found to directly induce IFIT1 mRNA transcripts, as well as to modu-
late the expression of IL12B and IL23AmRNA expression, thus proving
its effectiveness. The most likely reason explaining why, currently, we
do not observe any IL12AmRNA expression in IFN𝛾-treated cells, con-
sists in the use of highly pure neutrophils that, in 1995, could not be
obtained, given the unavailability of technologies such as cell depletion
by antibody-coated magnetic beads.39 Accordingly, we have repeat-
edly evidenced not only how crucial it is to work with highly pure pop-
ulations of neutrophils for gene expression studies, but also the neces-
sity to unequivocally exclude the possibility that a very low percentage
of contaminating cells could determine false positive results ultimately
attributed to neutrophils.7 In such regard, we have recently attempted
to clarify controversies concerning the ability of human neutrophils to
produce IFN𝛼,6 IL-10,40 and IL-17.41 Even in our indicted paper20 we
made our best in trying to purify neutrophils at the highest possible
levels of purity, compatibly with the technological means in possession
at those times. Whatever the case is, the unexpected results herein
described imply that neutrophils incubated with IFN𝛾 plus either LPS
or R848 can produce neither IL-12A nor IL-12, unlike IFN𝛾 plus R848-
or LPS-treated monocytes. It follows that our original data on the abil-
ity of IFN𝛾 plus LPS-treated neutrophils to produce extracellular IL-12
in vitro must be denied. Even though our current negative data in vitro
do not relate to themany studies reporting neutrophil-derived IL-12 in
vivo,42,43 we apologize for having unintentionally confused the scien-
tific community.
In the experiments in which neutrophils were incubated with IFN𝛾
plus eitherR848or LPS,we foundan inductionof the IL27A transcripts.
Because the same phenomenon did not occur if the three stimuli were
used alone, it is evident that IFN𝛾 plus either R848 or LPS synergize
to promote the transcription of the IL27A gene. Although the molec-
ular bases of such synergism were not addressed, data prompted us
to evaluate whether IL-27 could be released by neutrophils treated
for 20 h with IFN𝛾 plus R848, but our ELISA measurement of the
related supernatants gave negative data. By contrast, supernatants
from IFN𝛾 plus R848-treated monocytes were found to contain quan-
tities of IL-27 higher than those detected in supernatants from mono-
cytes treated with R848 only. It is therefore possible that the IL27A
mRNA induced in IFN𝛾 plusR848-treatedneutrophils is translated, but
not released, because it is stored in intracellular compartments, simi-
lar to what was observed for instance in the case of CXCL8,44 BAFF,45
or TRAIL.46 An alternative possibility is that IL-27 mRNA induced by
IFN𝛾 plus R848-mRNA is not translated at all, maybe because it is sub-
jected tomicroRNA-dependent regulatory controls.47 The latter possi-
bility might be in line with other findings observed in neutrophils incu-
bated with R848 in combination with TNF𝛼. Accordingly, R848 plus
TNF𝛼 were found to additively induce the levels of EBI3 mRNA, but
not those of EBI3 production, suggesting that regulatory mechanisms
controlling also EBI3 translation or intracellular accumulation/release
might take place in neutrophils.
In sum, the present study demonstrates that human neutrophils
incubated with TLR8 ligands and TNF𝛼 are able to produce remark-
able amounts of EBI3 in vitro. Importantly, our experiments also sug-
gest thatR848, LPS and, to a lesser extent, TNF𝛼, all induceEBI3mRNA
also in murine neutrophils isolated from peritoneum or BM. This indi-
cates that the capacity of neutrophils to respond to proinflammatory
stimuli in terms of EBI3 mRNA induction is conserved among species
and represents an important phenomenon.Moreover, immunostaining
studies support our in vitro findings, as they evidence an in vivo expres-
sion of EBI3 by neutrophils infiltrating tissues from discrete patholo-
gies, suchasGorhamdisease, diverticulitis, cholecystitis, andBartonella
Henselae infection, but not others, including primary carcinomas, psori-
asis, Chron’s disease, and COVID-19 pneumonia. Because EBI3mRNA
expression were found absent in peripheral neutrophils freshly iso-
lated from cohorts of active systemic lupus erythematosus (SLE) or
CMV-infected patients (our unpublished observations), it is clear that,
as in vitro, also in vivo, EBI3 expression becomes detectable in neu-
trophils only in certain pathologies. Why the latter occurs remains to
be investigated and explained. Given that as a self-standing molecule
EBI3hasbeen, for example, involved in thepathogenesis of rheumatoid
arthritis,48 inflammatory bowel disease,49 systemic sclerosis,12 and
cardiac inflammation,50 as well in growth-promoting activity of lung51
breast,52 and colorectal cancer,53 other than representing anovel diag-
nosis marker in Burkitt and diffuse large B-cell lymphoma,54 further
studies are necessary to clarify what is the effective function and bio-
logic meaning of neutrophil-derived EBI3 under these latter and other
circumstances.
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